Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002621 · ClinicalTrials.gov registry record · Phase 2
Interferon Alfa in Treating Children With HIV-Related Cancer
A Phase 2 study of Lymphoma and Leukemia, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 10
- Study locations
NCT00002621 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by Children's Oncology Group. The registered enrollment target is 8 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT00002621, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 10
- Study locations
Study Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating children with an HIV-related cancer including leukemia, non-Hodgkin's lymphoma, CNS lymphoma, or other solid tumors.
Conditions Studied
Interventions
- BIOLOGICAL recombinant interferon alfa
Study Locations (10)
Texas
- Medical City Dallas Hospital - Dallas
- San Antonio Military Pediatric Cancer and Blood Disorders Center - Lackland Air Force Base
- University of Texas Health Science Center at San Antonio - San Antonio
Other
- University of Puerto Rico School of Medicine Medical Sciences Campus - San Juan
- Clinique de Pediatrie - Geneva
Kansas
- Via Christi Regional Medical Center - Wichita
Louisiana
- MBCCOP - LSU Health Sciences Center - New Orleans
New Jersey
- Tomorrows Children's Institute - Hackensack
North Carolina
- Mission Saint Joseph's Health System - Asheville
Quebec
- McGill University Health Center - Montreal Children's Hospital - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 1994-12 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002621
The ClinicalTrials.gov registry entry for NCT00002621 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which recombinant interferon alfa is the first listed.
NCT00002621 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Texas, Other, Kansas.
Frequently Asked Questions
What is clinical trial NCT00002621 about?
NCT00002621 is a clinical study titled "Interferon Alfa in Treating Children With HIV-Related Cancer". RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating children with an HIV-related cancer including leukemia, non-Hodgkin's lymphoma, CNS lymphoma, or other solid tumors.
What is the current status of trial NCT00002621?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 1994-12. Estimated completion is 2005-09.
What conditions does trial NCT00002621 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00002621?
The interventions under investigation include: recombinant interferon alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002621?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002621 being conducted?
This trial has 10 study locations across Kansas, Louisiana, New Jersey, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.